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Introduction
Human cytomegalovirus (HCMV) establishes lifelong infection 
in the face of robust humoral and cell-mediated immune respons-
es. The virus is a significant cause of morbidity and mortality in 
immunocompromised individuals such as transplant recipients 
and patients with HIV and following congenital infection. A vac-
cine against HCMV is considered to be the highest priority, par-
ticularly for the prevention of congenital disease (1), but none has 
been licensed. The standard for treatment is therefore antiviral 
agents, however, these are limited by toxicity and the emergence 
of resistant strains (2).
As an alternative, antibody (Ab) responses have been investi-
gated as a basis for improved vaccines and immunotherapies (3–9). 
Several lines of evidence support a protective role for Abs in infec-
tion, including observational studies of natural immunity, which 
have documented a correlation between Ab titers and the preven-
tion of intrauterine transmission (10–13). Moreover, the admin-
istration of hyperimmune globulin (HIG) can improve survival in 
patients undergoing solid organ transplantation (14), and Ab titers 
correlated with protection in vaccine trials (8, 9). As a result, a range 
of Abs directed against virion envelope glycoproteins that are capa-
ble of neutralizing the entry of cell-free virus have been developed 
(5, 15, 16). However, neutralizing monoclonal antibodies (mAbs) 
administered as therapies have had only modest effects and/or 
failed to meet primary endpoints in clinical trials, namely, a reduc-
tion in viremia and/or the need for preemptive therapy (17, 18).
One potential explanation for this lack of clinical efficacy lies 
in the biology of virus dissemination. Spread between individuals 
involves cell-free virus, which can be efficiently inhibited by neu-
tralizing Abs. In contrast, dissemination within a host likely relies 
primarily on direct cell-to-cell spread (19–24), which is resistant 
to neutralizing antibodies (25), irrespective of the Ab repertoire of 
the donor (26). Thus, although classical neutralizing Abs may have 
a role in preventing transmission between people, they may be 
less effective in preventing the spread of virus within an individ-
ual. This is consistent with clinical trials of a subunit gB vaccine, 
in which protection correlated with Ab levels, but the induced 
antibodies did not exhibit overt neutralizing activity (27, 28). 
We therefore sought to prioritize Ab-based immunotherapeutic 
approaches that could target infected cells directly.
NK cells are crucial for virus control in vivo (29). This fact is 
highlighted by the impressive arsenal of HCMV-encoded immune 
evasins that act in consort to suppress NK cell activation through 
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CD57+ and NKG2C+ cell populations, and the levels of degranula-
tion were virtually indistinguishable between them. As NKG2C+ 
NK cells are rarely present in uninfected individuals, and up to 4% 
of people do not harbor the corresponding gene (KLRC2), subse-
quent data were recorded for CD57+ NK cells.
Cytotect enhanced NK cell activation at a minimum concen-
tration of 12.5 μg/mL and became progressively more potent as 
concentrations increased to 50 μg/mL, representing a relative-
ly steep activation curve (Figure 1A). Experiments were capped 
at this maximum, because increased background activation was 
observed with higher concentrations of IgG Abs from HCMV- 
seronegative donors. Interestingly, efficacy was not dependent on 
NK cell stimulation, since equivalent results were obtained wheth-
er or not cells were preincubated with IFN-α (Figure 1, A and B). 
Given that HCMV actively represses the release of IFNs (48), this 
supports an important role for ADCC in rapidly activating NK cells 
against HCMV without a requirement for additional stimulations.
When the sensitivity of HCMV-infected cells to ADCC was 
investigated over the course of infection, we detected NK cell 
activation as early as 24 hours post infection (hpi), irrespective of 
preincubation with IFN-α, but this increased dramatically at 48 
hpi (Figure 1, C and D) before decreasing slightly at 72 hpi. This 
reduction may be related to the expression at this later time point 
of viral FcRs and other NK inhibitors, which antagonize ADCC 
(32, 45, 49). HCMV antigens expressed on the cell surface by 48 
hpi are therefore recognized by naturally occurring Abs and act as 
effective targets to drive ADCC. Importantly, HCMV has a slow 
replication cycle, with virions not produced in significant num-
bers until 72 hpi, so these observations highlighted a therapeutic 
opportunity to limit the dissemination of HCMV.
HCMV downregulates, but does not abrogate, the expression 
of endogenous HLA class I molecules. NK cell activation may 
therefore be influenced by interactions between residual HLA-I 
and killer immunoglobulin-like receptors (KIRs). To address 
this possibility, we investigated NK cell recognition of allogeneic 
and autologous targets in the context of ADCC. The potency of 
HCMV-encoded NK cell evasion functions is illustrated by the 
fact that uninfected autologous and allogeneic targets activat-
ed NK cells much more efficiently than did the corresponding 
HCMV-infected targets (Figure 1, E and F). However, in both cas-
es, the inclusion of seropositive Abs overcame the strong protec-
tive effects of HCMV-encoded NK evasion functions to stimulate 
high levels of NK cell activation, irrespective of preincubation with 
IFN-α (Figure 1, E and F). Thus, the addition of anti-HCMV Abs 
was able to potently activate NK cells and overcome viral immune 
evasion prior to the production of new virions, irrespective of NK 
cell stimulation or engagement of HLA-I.
Antigens expressed on the cell surface at 48 hpi promote ADCC. 
ADCC has the potential to target infected cells during the early 
phase of the HCMV replication cycle. To determine which viral 
antigens primed ADCC, we reanalyzed data from our quantita-
tive temporal viromics investigation of the HCMV-infected cell- 
surface proteome (45). We identified 3 clear kinetic classes of pro-
tein expression (Figure 2A). Ten proteins reached at least 25% of 
their maximal cell-surface levels by 24 hpi, and an additional 5 
proteins reached at least 25% of their maximal levels by 48 hpi. 
Thus, a substantial number of viral proteins are trafficked to the 
the manipulation of ligands for activating and inhibitory receptors 
(30, 31). However, in addition to working through these receptors, 
NK cells participate in Ab-dependent cellular cytotoxicity (ADCC) 
(32, 33). ADCC involves the activation of NK cells upon engage-
ment of Fc receptors (FcRs) on the NK cell surface, with the Fc 
portion of an Ab bound to a target cell. In vivo, HCMV infection 
is associated with a dramatic expansion of “adaptive” NK cells 
marked by the expression of CD94/NKG2C, and CD57 and by 
the loss of FcεR1γ (29, 34). These cells are exceptionally efficient 
at mediating ADCC (35–38) and have been associated with pro-
tection from disease (35, 39–41). Accordingly, ADCC may be an 
important mechanism of immune control during natural infec-
tion. In this scenario, Abs act as critical stimulators of cellular 
immunity, rather than acting through virus neutralization.
We were therefore interested in how ADCC operated in the 
context of an HCMV infection and whether it could be exploited 
for therapeutic use. We found that anti-HCMV Abs could activate 
NK cells early after HCMV infection, prior to the production of 
new virions, and that these Abs had a remarkable capacity to over-
whelm the potent HCMV-encoded NK cell evasion mechanisms 
in vitro. We have previously exploited the power of proteomics to 
characterize viral and host gene expression during HCMV infec-
tion in unparalleled detail, revealing the ways in which the virus 
manipulates the host cell to promote survival, and to identify ways 
of counteracting the virus through antiviral restriction factors 
(33, 42–47). Here, we combined this technique with functional 
immunological screening to identify the targets on the infect-
ed cell surface that mediate antiviral ADCC. Surprisingly, these 
techniques revealed that the optimal targets were not the struc-
tural glycoproteins that are traditionally assumed to be ADCC 
targets, but immune evasins that are expressed earlier during the 
viral life cycle. Their identification enabled us to isolate human 
mAbs directed against these targets that, once we had genetically 
engineered them, could activate NK cells in response to HCMV- 
infected cells. Thus, our technologies enabled the identification of 
optimal antigenic targets for the development of antiviral thera-
peutics, and the isolation of what we believe to be the first human 
mAbs targeting a single HCMV protein that are sufficient to medi-
ate enhanced NK activation through ADCC, despite virus-encod-
ed immune evasins. Our platform is therefore capable of generat-
ing novel antiviral immunotherapies that can efficiently activate 
antiviral cellular immunity.
Results
HCMV-infected cells are susceptible to ADCC during the early phase of 
infection. We examined the ability of Cytotect (clinical-grade HIG 
pooled from donors with high anti-HCMV–neutralizing titers) to 
enhance NK cell activation in the presence of target cells infected 
with a HCMV strain (Merlin) expressing the complete repertoire 
of virally encoded immune evasins. Since adaptive NK cells are 
the primary mediators of ADCC in PBMCs from HCMV-seroposi-
tive donors (29, 35–38), we examined the activation of CD56+ NK 
cells in the CD57+ and NKG2C+ subsets, measuring degranulation 
via surface mobilization of CD107a. Both cell populations demon-
strated a greater enhancement of degranulation when Ab was add-
ed, compared with the NKG2C–CD57– cell population. However, 
in the majority of donors, we observed a large overlap between the 
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mediate ADCC in the context of HCMV infection, we generated 
a series of mAbs. RL11 is an Fc-binding protein (50) that com-
plicates both the production of specific Abs and the analysis of 
functional assays. US28 is a type 3 transmembrane protein, and 
thus the generation of US28-specific Abs would be less straight-
forward. Therefore, RL11 and US28 may not provide routine tar-
get antigens. Further, since UL5 was associated with only modest 
levels of NK cell activation, the type 1 membrane proteins UL16 
and UL141 were prioritized. Sequences encoding the extracellular 
domains of each protein were cloned  as modified constructs with 
a C-terminal 6xHis-tag (UL16) or a C-terminal Strep-tag (UL141) 
into separate RAd vectors for expression. The corresponding pro-
teins were purified from cell supernatants via affinity chromatog-
raphy, labeled with fluorochromes, and used as probes to stain 
IgG+ B cells from a donor infected with HCMV. UL141-specific B 
cells were more numerous than UL16-specific B cells (Figure 3A). 
Single antigen-specific B cells were then flow-sorted into culture 
medium containing CD40L+ feeders, IL-2, IL-4, IL-21, and B cell 
activating factor (BAFF) to generate plasma cells (51). All secret-
ed mAbs were then screened against cells expressing UL16 or 
UL141. Both proteins contain an ER retention signal in the C-ter-
minal cytoplasmic domain, which restricted cell-surface expres-
cell membrane prior to the production of new virions. Further-
more, multiple proteins reached a maximal overall abundance 
equal to or higher than that of structural proteins expressed during 
the later phases of infection (Figure 2B). Therefore, targeting pro-
teins expressed early during the viral life cycle is likely to be equal-
ly as effective as targeting later-expressed factors. An analysis of 
the partitioned abundance of each protein over time indicated that 
UL16, RL12, UL141, and US28 were expressed on the cell surface 
at 48 hpi, were among the most abundant viral proteins at this 
time point, and would therefore be potential candidates for ADCC 
targets (Figure 2C).
On the basis of these results, we generated replication- 
deficient adenovirus (RAd) vectors expressing each of the 15 
viral proteins that were reproducibly identified on the surface of 
HCMV-infected cells by 48 hpi (Figure 2D). Each RAd was then 
tested individually for its capacity to promote ADCC in the pres-
ence of pooled polyclonal HIG (Figure 2E). UL16, UL141, US28, 
RL11, and UL5 each induced a significant increase in NK cell acti-
vation that was dependent on the presence of Cytotect, indicating 
that these viral antigens could induce early-phase ADCC.
Abs directing ADCC can be isolated from human donors. To 
investigate whether the identified viral protein targets could 
Figure 1. Characterization of ADCC- 
mediated NK cell activation against 
HCMV-infected fibroblasts. HFFFs 
immortalized with hTERT or similarly 
immortalized autologous SFs were 
infected with HCMV strain Merlin. 
Mock-infected HF-TERTs or SFs were 
included as controls. (A and B) Percent-
age of degranulation of CD56+CD57+ NK 
cells among PBMCs in the presence of 
HF-TERTs infected for 48 hours with 
HCMV and different concentrations 
of either Cytotect or seronegative 
IgGs (Neg IgG). PBMCs were either 
untreated (A) or pretreated for 18 hours 
with IFN-α (B). (C and D) Percentage 
of degranulation of CD56+CD57+ NK 
cells among PBMCs in the presence 
of HF-TERTs infected for 24 hours, 
48 hours, or 72 hours with HCMV and 
either Cytotect or seronegative IgGs 
(each at 50 μg/mL). PBMCs were either 
untreated (C) or pretreated for 18 hours 
with IFN-α (D). (E and F) Percentage of 
degranulation of CD56+CD57+NKG2C+ NK 
cells among PBMCs in the presence of 
HF-TERTs (E) or SFs (F) infected for 48 
hours with HCMV and either Cytotect or 
seronegative IgGs (each at 50 μg/mL). 
Results are representative of at least 3 
experiments. All data are shown as the 
mean ± SD of triplicate samples.  
*P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001, by 2-way ANOVA.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(3):e139296  https://doi.org/10.1172/JCI1392964
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5J Clin Invest. 2021;131(3):e139296  https://doi.org/10.1172/JCI139296
ilar, despite the diversity of their antigen binding (Fab) sequences. 
When the 5 mAbs were mixed together at equimolar concentra-
tions, the ADCC effect was not enhanced beyond the level of each 
individual Ab. These findings suggested that each mAb targeted the 
same immunodominant epitope with similar efficiency, irrespec-
tive of diversity in the corresponding antigen-binding domains.
In contrast, only 2 of the UL141-specific mAbs were capable of 
mediating ADCC in isolation, and activation was extremely weak 
(Figure 4B). However, when all 8 purified Abs were mixed togeth-
er at equal concentrations, ADCC was efficiently activated. Three 
of the Abs were prone to eliciting nonspecific activation against 
control infected cells, and therefore we tested a mixture of the oth-
er 5 Abs and found them to be equally capable of activating ADCC, 
but with reduced background levels (Figure 4B). The fact that anti-
UL141 mAbs stimulated higher levels of degranulation when used 
as a mixture suggests that at least some of them bind to different 
epitopes on UL141. In dose-titration experiments against the cor-
responding targets, mixtures of UL16-specific or UL141-specific 
mAbs maximally activated NK cells at concentrations above 15 
μg/mL (Figure 4, C and D), indicating greater efficacy compared 
with Cytotect (Figure 1, A and B).
Although these results were encouraging in terms of therapeu-
tic development, pooled mAbs specific for UL16 or UL141 were 
unable to activate NK cells in the presence of targets infected with 
HCMV, even though Cytotect was effective (Figure 4, E and F). 
HCMV encodes 4 Fc-binding proteins (FcRs) (RL11, RL12, RL13, 
and UL119) that have the potential to antagonize ADCC. Accord-
ingly, human IgGs bound cells infected with an HCMV-mutant 
strain lacking all 4 of these genes (HCMVΔFc) to a lesser extent 
than they bound cells infected with wild-type HCMV (Supple-
mental Figure 3A). However, NK cells were activated similarly 
under both conditions in the presence of Cytotect (Supplemental 
Figure 3B). The lack of efficacy of the specific Abs against HCMV- 
infected cells was therefore not caused by antagonism of ADCC 
by viral FcRs. It may reflect lower levels of protein on the cell sur-
face during HCMV infection compared with RAd expression (Sup-
plemental Figure 3C), or the concerted action of multiple virally 
encoded immune evasins that inhibit NK activation (30).
Ab engineering enables mAbs to activate ADCC against HCMV. A 
major advantage of cloned mAbs is that they can be manipulated to 
enhance different effector functions. We took advantage of this to 
optimize the ability of our mAbs to activate ADCC by introducing 2 
amino acid sequence changes into the Fc region that had previous-
ly been shown to enhance binding to CD16 on NK cells (52). In line 
with previous data indicating that viral and host FcRs bind Fc in dif-
ferent ways (53), these modifications did not affect binding to viral 
FcRs (Supplemental Figure 3, D and E). Dose-titration experiments 
revealed that mixtures of engineered mAbs specific for UL16 or 
UL141 activated NK cells more potently and at much lower con-
centrations than did the corresponding unmodified mAbs (Figure 
5, A and B) or Cytotect (Figure 5, C and D). As before, when tested 
separately, all of the mAbs against UL16 activated ADCC, and we 
observed no increase in activation when they were combined (Fig-
ure 5E). However, unlike the unmodified versions, all the modified 
UL141 mAbs activated ADCC individually (Figure 5F). Moreover, 
they retained the ability to show enhanced activation when used 
in combination, whether as a mixture of 5 or 8 mAbs (Figure 5F).
sion (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI139296DS1). 
To increase the sensitivity of this flow cytometry–based Ab screen, 
we increased the cell-surface abundance of target antigens by 
deleting this region (Supplemental Figure 1A). Screening 60 B cell 
supernatants against these proteins revealed that 9 bound UL141 
and 5 bound UL16 (Supplemental Figure 1B).
B cell receptor (BCR) sequencing revealed that the predict-
ed amino acid sequences of these mAbs were diverse and incor-
porated both κ and λ light chains, suggesting that Abs had the 
potential to target distinct epitopes (Supplemental Figure 2). We 
subcloned the variable domains of these BCRs into an expression 
plasmid that provided a human IgG1 backbone, with the specif-
ic purpose of optimizing the utility of the Ab fusion for ADCC. 
When expressed, these recombinant human mAbs retained their 
capacity to bind to UL141 and UL16 on the cell surface (Figure 3, B 
and C), but not to denatured antigen (Figure 3D), suggesting that 
all bind to conformational epitopes.
Anti-UL16 and anti-UL141 human mAbs activate ADCC when 
antigen is expressed in isolation. Although the mAbs bound to UL16 
and UL141 when optimized for high expression on the cell surface 
(Figure 3, B and C), binding to the natural forms was not detect-
able by flow cytometry (Figure 3, E and F, Supplemental Figure 
1A), indicating that very low levels of these proteins naturally traf-
fic to the cell surface. Nevertheless, ADCC assays appeared more 
sensitive than flow cytometry, as the natural versions of both 
genes were able to induce ADCC with both Cytotect and mAbs 
(Figure 4, A and B).
Each novel UL16 mAb was readily able to drive ADCC against 
fibroblasts expressing wild-type UL16 with an efficiency com-
parable to that observed with Cytotect (Figure 4A). The level of 
ADCC elicited by different anti-UL16 mAbs was remarkably sim-
Figure 2. Identification of viral proteins on the plasma membrane that 
could prime ADCC. (A) Temporal profiles of viral proteins (n = 27) identified 
previously on the surface of cells infected with HCMV. Proteins were only 
included in the analysis if detected in experiments PM1 and PM2 and 
quantified by 2 or more peptides in experiment PM1 or experiment PM2. 
Data are shown for experiment PM2. Proteins are grouped on the basis 
of expression kinetics, indicating that greater than 25% of the maximal 
signal was reached by 24 hours (left), 48 hours (middle), or 72 hours (right). 
(B) Average total abundance of each surface-expressed viral protein mea-
sured using IBAQ. Error bars indicate ranges from experiments PM1 and 
PM2. (C) Partitioned IBAQ abundance of each surface-expressed viral pro-
tein over time. Average IBAQ abundance values in B were multiplied by the 
fractional abundance at each time point from A. (D) HF-TERTs transfected 
with the coxsackie-adenovirus receptor (HFFF-hCARs) were transduced 
with RAds expressing individual viral proteins. An identical vector lacking a 
transgene was used as a control. Surface-expressed proteins were isolated 
by aminooxy biotinylation followed by immunoprecipitation with strepta-
vidin beads 48 hours after transduction. Western blots show detection of 
the C-terminal V5 tags engineered into each protein, with the exception 
of UL141, which was detected with a UL141-specific Ab. UL141 staining 
of the gel was performed separately but is overlaid on the same image. 
(E) Percentage of degranulation of CD56+CD57+ NK cells among PBMCs 
in the presence of HFFF-hCARs, transduced as in D, and either Cytotect 
or seronegative IgGs (each at 50 μg/mL). Results are representative of 3 
experiments. Data are shown as the mean ± SD of triplicate samples (E). 
*P < 0.05 and ****P < 0.0001, by 2-way ANOVA. ctrl, control. 
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Figure 3. Anti-UL16 and anti-UL141 mAbs can be isolated and cloned from seropositive donors. (A) IgG+ B cells from a HCMV-seropositive donor were 
stained with fluorescently labeled UL16 or UL141 proteins to sort B cells expressing specific mAbs. FSC, forward scatter; SSC, side scatter. (B and C) HFFF-
hCARs were transduced with RAds expressing UL141 or UL16 lacking their ER retention signals. Cells were stained with the cloned human anti-UL141 or 
anti-UL16 mAbs and analyzed by flow cytometry. Cytotect was used as a positive control. (D) HFFF-hCARs were transduced with RAds lacking a transgene, 
or RAds expressing wild-type forms of UL141 or UL16. Samples were lysed, separated by SDS-PAGE, and analyzed by immunoblotting using human anti-
UL16 or anti-UL141 mAbs. As a positive control, the UL16 lysate was stained with an anti-V5 Ab, and the UL141 lysate was stained with a murine anti-UL141 
Ab. (E and F) HFFF-hCARs were transduced with RAds expressing wild-type forms of UL141 or UL16. Forty-eight hours later, they were stained with human 
anti-UL141 or anti-UL16 mAbs or Cytotect and then analyzed by flow cytometry.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
7J Clin Invest. 2021;131(3):e139296  https://doi.org/10.1172/JCI139296
Next, we tested the efficiency of the mAbs in the context of 
HCMV infection both separately and in combination. Even in their 
modified form, the anti-UL16 mAbs were not able to reproducibly 
activate ADCC against HCMV-infected cells (Figure 6, A–C). In 
contrast, ADCC was efficiently achieved against HCMV using 
the modified anti-UL141 mAbs. Individually, we found that these 
mAbs only activated ADCC very weakly, but the combination of 
5 Abs was successful at activating ADCC almost as effectively 
as Cytotect, despite being used at a 40-fold lower concentration 
(Figure 6, D and E). This effect was highly specific, because acti-
vation was not apparent when a virus lacking the cognate antigen 
was used (Figure 6F). Furthermore, these Abs were also capable of 
activating NK cells to secrete TNF-α and IFN-γ, indicating potent 
antiviral effector functions in the presence of targets infected with 
HCMV (Figure 6, G and H).
Finally, we examined the ability of our mAbs to promote 
direct killing of cells. Measuring short-term cytotoxicity using 
chromium-release assays revealed that a mixture of 5 modified 
anti-UL141 Abs led to a substantial increase in NK-mediated cell 
death when UL141 was expressed in isolation (Figure 7A), or when 
fibroblasts were infected with HCMV (Figure 7B). This effect was 
not restricted by cell type, because we obtained similar results 
Figure 4. Human anti-UL16 and anti-UL141 mAbs activate ADCC efficiently against adenovirally expressed UL16 and UL141. (A–D) HFFF-hCARs were 
transduced with RAds expressing wild-type UL16 or UL141. An identical vector lacking a transgene was used as a control. (A) Percentage of degranulation 
of CD56+CD57+ NK cells among PBMCs in the presence of transduced HFFF-hCARs and Cytotect (40 μg/mL), seronegative IgGs (40 μg/mL), or UL16- 
specific mAbs (each at 30 μg/mL). All 4 mAbs were included at equimolar concentrations in the mixture. (B) As in A for UL141. Five mAbs were included 
at equimolar concentrations in 1 mixture (B2, D3, G3, G4, and G11), and 8 mAbs were included at equimolar concentrations in another mixture (B2, C3, D3, 
E5, G2, G3, G4, and G11). (C) Percentage of degranulation of CD56+CD57+ NK cells among PBMCs in the presence of transduced HFFF-hCARs and different 
concentrations of the tetravalent UL16-specific mAb mixture. (D) As in C for the pentavalent UL141-specific mAb mixture. (E and F) HF-TERTs were infect-
ed with HCMV strain Merlin. Mock-infected HF-TERTs were included as controls. (E) Percentage of degranulation of CD56+CD57+ NK cells among PBMCs in 
the presence of infected HF-TERTs and Cytotect, seronegative IgGs, or the UL16-specific mAb mixture (each at 30 μg/mL). (F) As in E for UL141. Results 
are representative of at least 3 experiments. Data are shown as the mean ± SD of triplicate samples (A–F). All experiments were performed 48 hours after 
transduction (A–D) or infection (E and F). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA.
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captures the effects of both cytotoxic and noncytotoxic virus con-
trol in a fully autologous system (Figure 7, D and E, and refs. 54, 
55). The UL141 mAbs demonstrated a striking ability to enhance 
NK-mediated virus control in this assay, confirming that they can 
act as powerful effectors for long-term control of virus infection, 
even at low effector/target (E/T) ratios.
Discussion
Multiple human anti-HCMV mAbs have been developed that tar-
get virus neutralization as their mechanism of action (5, 17, 18, 56–
58). Although these mAbs offer advantages over HIG, in that they 
are defined products with a specific activity, the highly cell-associ-
when HCMV infected epithelial cells were used (Figure 7C). Fur-
thermore, our defined Abs markedly outperformed Cytotect in 
these assays, despite being used at a lower concentration. Inter-
estingly, unlike in degranulation assays (Supplemental Figure 3B), 
when we performed cytotoxicity experiments, the viral FcRs did 
limit cell death, since killing was significantly enhanced in their 
absence (Figure 7B). However, this effect was more pronounced 
with Cytotect than with our engineered mAbs. Thus, Ab engi-
neering to enhance NK cell activation may also improve function 
by overcoming viral countermeasures. We also investigated the 
ability of the UL141 mAbs to promote the control of virus using a 
recently developed 10-day viral dissemination assay (VDA), which 
Figure 5. Optimized anti-UL16 and anti-UL141 mAbs activate ADCC efficiently against adenovirally expressed UL16 and UL141. HFFF-hCARs were 
transduced with RAds expressing wild-type UL16 or UL141. An identical vector lacking a transgene was used as a control. (A) Percentage of degranulation 
of CD56+CD57+ NK cells among PBMCs in the presence of transduced HFFF-hCARs and different concentrations of native or Fc-engineered (modified) 
UL16-specific mAbs (tetravalent mixes). (B) As in A for UL141 (pentavalent mixes). (C) Percentage of degranulation of CD56+CD57+ NK cells among PBMCs 
in the presence of transduced HFFF-hCARs and Cytotect, seronegative IgGs, or tetravalent mixes of native or Fc-engineered (modified) UL16-specific mAbs 
(native Abs each at 30 μg/mL; Fc-engineered [modified] mAbs each at 1 μg/mL). (D) As in C for UL141 (pentavalent mixes). (E) As in C for individual Fc- 
engineered (modified) UL16-specific mAbs. (F) As in D for individual Fc-engineered (modified) UL141-specific mAbs. Results are representative of at least 
3 experiments. All data are shown as the mean ± SD of triplicate samples. All experiments were performed 48 hours after transduction. ***P < 0.001 and 
****P < 0.0001, by 2-way ANOVA. Mod, modified.
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and has been implicated in the control of multiple different virus-
es, including West Nile virus, smallpox virus, herpes simplex 
virus, influenza virus, yellow fever virus, Ebola virus, and Epstein-
Barr virus. It also correlates with control of HIV in both vaccina-
tion and natural infection (59, 60) and is thought to underlie the 
ated nature of clinical HCMV strains and the intrinsically greater 
resistance to neutralization of cell-to-cell spread in comparison 
with cell-free entry mean that their ability to prevent intra-host 
spread may be limited (25, 26). In contrast, Ab-mediated activa-
tion of cellular immunity does not suffer from these limitations 
Figure 6. Anti-UL141–optimized Abs activate ADCC efficiently against HCMV. HF-TERTs were infected with HCMV strain Merlin (A–H) or Merlin ΔUL16 
ΔUL141 (C and F). Mock-infected HF-TERTs were included as controls. (A) Percentage of degranulation of CD56+CD57+ NK cells among PBMCs in the 
presence of infected HF-TERTs and different concentrations of Fc-engineered (modified) UL16-specific mAbs (tetravalent mixture). (B) Percentage of 
degranulation of CD56+CD57+ NK cells among PBMCs in the presence of infected HF-TERTs and Cytotect (40 μg/mL), seronegative IgGs (40 μg/mL), or 
Fc-engineered (modified) UL16-specific mAbs tested individually or in combination (each at 1 μg/mL). (C) Percentage of degranulation of CD56+CD57+ NK 
cells among PBMCs in the presence of infected HF-TERTs and Cytotect (40 μg/mL), seronegative IgGs (40 μg/mL), or the tetravalent mixture of Fc- 
engineered (modified) UL16-specific mAbs (each at 1 μg/mL). Activity was tested against HF-TERTs infected with Merlin or Merlin ΔUL16 ΔUL141. (D) As 
in A for UL141 (pentavalent mixture). (E) As in B for UL141. (F) As in C for UL141. (G) Percentage of intracellular TNF-α production by CD56+CD57+ NK cells 
among PBMCs in the presence of infected HF-TERTs and Cytotect (50 μg/mL), seronegative IgGs (50 μg/mL), or Fc-engineered (modified) UL141-specific 
mAbs tested individually or in combination (each at 1 μg/mL). (H) As in G for IFN-γ. Results are representative of at least 3 experiments. Data are shown 
as the mean ± SD of triplicate samples (A–H). Experiments were performed 48 hours after infection (A–F). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P 
< 0.0001, by 2-way ANOVA.
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all the more impressive that our technologies enabled the devel-
opment of Abs capable of reversing the ability of viral immune 
evasins to inhibit NK cell activation, even when the HCMV strain 
expressed the complete repertoire of genes present in a clinical 
isolate (19, 20, 33). In addition to encoding functioning immune 
evasins, it seems likely that HCMV has evolved to restrict cell- 
surface expression of viral proteins in order to minimize ADCC. 
As a result, the extreme sensitivity of mass spectrometry was 
required in order to identify viral cell-surface antigens. Neverthe-
less, although cell-surface antigen levels were extremely low, it is 
clear that ADCC had evolved to be extraordinarily sensitive, with 
Ab engineering enabling strong NK activation to occur despite Ab 
binding being undetectable by flow cytometry, underscoring the 
potential of our pipeline to produce highly effective Abs. The strict 
species specificity of CMVs and the fact that our primary targets 
(UL16 and UL141) are not conserved in mouse or rat CMV, and 
show only 32% homology in rhesus CMV, preclude efficacy test-
ing of our Abs in animal models. Future work will be required to 
demonstrate both safety and efficacy in humans.
efficacy of numerous antitumour Abs in clinical development (61, 
62). There is thus considerable interest in exploiting this power-
ful mechanism of control across multiple pathogens and diseas-
es. However, this requires mapping of the antigens that optimally 
activate ADCC and production of cloned human mAbs capable 
of mediating ADCC. Our demonstration that plasma membrane 
proteomics and functional immunology can be combined to iden-
tify novel ADCC targets not only opens up a fuller understanding 
of natural immunity against HCMV that can now be exploited for 
therapeutic benefit, but is also applicable to exploiting Ab-medi-
ated activation of cellular immunity in other infectious diseases, 
and potentially even cancer.
As a virus that persists lifelong, HCMV faces major challenges 
in avoiding being cleared by the immune response and, as a result, 
has evolved an exceptionally broad range of techniques to limit 
immune activation (30, 31). The study of these has revealed details 
about the underlying functioning of the immune system, but also 
shows that the virus poses a particular challenge to the develop-
ment of methods to activate antiviral immunity. It is therefore 
Figure 7. Anti-UL141–optimized Abs mediate efficient killing of HCMV-infected cells. (A–C) 51Cr release into the supernatant was used as a measure 
of the ability of NK cells to kill target cells. Targets were mixed with ex vivo–purified NK cells as effectors at a an E/T ratio of 20:1, and 51Cr release was 
measured 4 hours later. Seronegative IgG (50 μg/mL), Cytotect (50 μg/mL), or a mixture of 5 Fc-engineered (modified) UL141-specific mAbs were included 
as indicated. Targets were HF-CARs infected with RAd vectors expressing UL141 (RAd-UL141), or lacking a transgene (RAd Ctrl) (A); HFFF mock infected or 
infected with wild-type HCMV (HCMV) or HCMV lacking the viral FcRs (ΔFc) (B); or ARPE19 mock infected or infected with wild-type HCMV (C). For ARPE19 
infection, cells were infected by coculturing with purified fibroblasts for 24 hours and then sorted to purity. All experiments were performed 48 hours after 
infection. (D and E) HCMV expressing mCherry linked to an immediate early gene (UL36), and EGFP linked to a late gene (UL32) were used to infect SFs at 
a low MOI. Autologous NK cells were then added alone or together with a control mAb or the mixture of 5 modified anti-UL141 mAbs (each at 1 μg/mL). 
Eight to 10 days later, the percentage of infected cells demonstrating expression of immediate early (D) or late (E) viral proteins were measured by flow 
cytometry for mCherry or EGFP, respectively, and normalized to the percentage of infected cells in the absence of NK cells. Results are representative of at 
least 2 experiments. Data are shown as the mean ± SD of triplicate samples. **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA.
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therapies has resulted in the development of multiple different 
Ab optimizations, which now become amenable to deployment 
against HCMV. This includes “arming” Abs with drugs or toxins, 
or converting them into bispecific or trispecific NK engagers to 
enhance ADCC efficacy even further (74). In addition to ADCC, 
surface-bound Abs can also activate phagocytosis, complement, 
and T cells (75) and can lead to an adaptive cellular response by 
binding to FcRs on DCs. The induction of such mechanisms, in 
addition to ADCC, has been shown to be effective at mediating 
tumour control (61, 62), and modifications exist to further opti-
mize these activities (76). Thus, the development of our mAbs 
provides a platform with which multiple aspects of the immune 
system can be armed, increasing efficacy in vivo even further. As 
well as opening up the possibility of exploiting optimized Abs for 
passive infusion, the cell-surface targets that we have identified 
could also be considered as part of a vaccine strategy. For exam-
ple, by vaccinating with UL141 protein, it may be possible to gen-
erate a polyclonal anti-UL141 Ab response, which could provide 
enhanced immunity via Fc-mediated effector functions. In this 
context, it will be important to determine the efficacy of ADCC 
Abs in controlling HCMV infection in individuals exhibiting dif-
ferent repertoires of NK cell subsets, including in those who are 
HCMV seropositive or seronegative and in individuals with larger 
or smaller numbers of adaptive NK cells.
In conclusion, we have developed a methodological pipeline 
combining proteomics with functional immunology, single-cell 
cloning, and molecular engineering that identified novel therapeu-
tic targets; revealed that “classical” cell-surface antigens were not 
necessarily the optimal targets; avoided potential issues with ADE; 
and produced Abs capable of binding targets and activating cellu-
lar immunity, despite the presence of multiple immune evasins and 
despite the fact that target expression levels can be too low to detect 
by flow cytometry. We anticipate that our approach will be gener-
ically applicable to other pathogens and tumors, both in terms of 
passive immunization and vaccine design, with broad implications 
for immunotherapeutic strategies beyond HCMV. However, here 
we used it to demonstrate that ADCC is an extraordinarily potent 
effector mechanism for activating NK cells against HCMV-infect-
ed cells. We have identified multiple cell-surface targets for the 
development of novel antiviral immunotherapies or vaccination 
strategies that can activate ADCC, and we have generated what we 
believe to be the first human Abs targeting a single HCMV antigen 
that are sufficient to activate ADCC. Together, we believe these 
results open the path for the development of novel immunothera-
peutic strategies that can activate multiple different arms of cellu-
lar immunity and enable enhanced control of HCMV in vivo.
Methods
Cells. Human fetal foreskin fibroblasts (HFFFs), HFFFs immortal-
ized with human telomerase reverse transcriptase (HF-TERTs) (77), 
HF-TERTs transfected with the coxsackie adenovirus receptor (HFFF-
hCARs) (78), TERT-immortalized healthy donor skin fibroblasts (SFs), 
and 293 TREX cells (Thermo Fisher Scientific) were grown under stan-
dard conditions in DMEM (Thermo Fisher Scientific) supplemented 
with 10% FCS, penicillin (100 U/m), and streptomycin (100 μg/mL). 
Expi293F suspension cells (Thermo Fisher Scientific) were maintained 
in a humidified, shaking incubator at 150 rpm, 37°C, and 8% CO2 and 
The choice of cell-surface antigen is likely to be an important 
parameter that defines the efficacy of mAbs that activate ADCC. 
Surprisingly, the antigens that we identified as mediating ADCC 
were not the classical viral structural proteins that ADCC studies 
have traditionally focused on. Our previous proteomics analy-
sis defined 5 temporal classes of viral gene expression (45), with 
examples from multiple classes found on the infected cell sur-
face. However, targeting those present 48 hpi offers a number of 
advantages. ADCC activity with polyclonal IgG from seropositive 
donors was as high at this time point as it was later in infection, 
implying that many of the antigens that prime ADCC-mediated 
control in healthy individuals are present within 48 hours. New 
virions have not yet formed, increasing the chances that cells will 
be killed before the virus can spread, and the abundance of the 
proteins we targeted was among the highest of any viral protein, at 
any time point. In addition, by focusing on nonstructural proteins, 
there was limited risk of inadvertently enhancing disease through 
Ab-dependent enhancement (ADE) of infection (63). Although 
we prioritized UL16 and UL141, US28 or RL11 may also be useful 
targets if suitable Abs can be generated, although at present this is 
not simple. Abs targeting US28 in particular could be important, 
since US28 is expressed during latency and there is evidence that 
polyclonal Abs targeting this protein can lead to the destruction of 
latently infected monocytes via neutrophil-mediated ADCC (64). 
Finally, our target antigens were chosen on the basis of their ability 
to activate ADCC with HIG. Some of the other cell-surface pro-
teins that we identified may also mediate ADCC effectively, but 
if they do not induce high Ab levels during natural infection, they 
would have remained silent in our functional assays. For these pro-
teins, murine immunization strategies could be used to generate 
additional ADCC-capable mAbs. Likewise, it is possible that some 
potential targets were missed by our mass spectrometry strategy if 
the peptides they generated ionized poorly.
It is notable that all of the targets identified in the present 
study are immune evasion genes. Among its many roles, US28 
acts as a cytokine sink on the cell surface (65). UL141 reduces 
the cell-surface expression levels of CD112 and CD155 (66, 67), 
which are ligands for the activating NK cell receptor DNAM1, as 
well as TRAIL receptors (68), while UL16 reduces cell-surface 
levels of ULBP1–3 and MICB, which bind to the activating NK cell 
receptor NKG2D (69, 70). It may be that both UL141 and UL16 
traffic to the cell surface to scavenge their targets. Accordingly, if 
viral mutants arose in vivo to evade Ab recognition, infected cells 
might become more susceptible to NK cell–mediated immune 
control, which in turn would hinder the widespread selection of 
such mutants. The use of multiple Abs targeting the same anti-
gen could also limit the selection of viral escape mutations. The 
sequences of both UL141 and UL16 are well conserved among 
clinical HCMV isolates, suggesting that Abs targeting them could 
control a broad range of virus strains (71, 72).
Cloned mAbs offer major advantages over polyclonal prod-
ucts such as HIG. They are defined products with consistent 
specificity over time, and molecular engineering can be used to 
optimize functionality for specific purposes. As a result, our mAbs 
activated ADCC at concentrations over 40-fold lower than that of 
Cytotect, something that may significantly enhance effectiveness 
in vivo (73). Furthermore, the generation of anticancer immuno-
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(3):e139296  https://doi.org/10.1172/JCI1392961 2
ment PM2 data, the proteins were grouped according to when greater 
than 25% of the maximum signal was reached. Abundance for each 
protein was normalized to a maximum of 1, as described previously 
(45). For Figure 2B, the method of intensity-based absolute quantifica-
tion (IBAQ) was adapted from the original description (87) to estimate 
the relative abundance of each of the 27 viral proteins. The maximum 
MS1 precursor intensity for each quantified peptide was determined, 
and a summed MS1 precursor intensity for each protein across all 
matching peptides was calculated, considering data for experiments 
PM1 and PM2 separately. Intensities were divided by the number of 
theoretical tryptic peptides from each protein between 7 and 30 ami-
no acid residues in length to give estimated IBAQ values. For each of 
experiments PM1 and PM2, the estimated IBAQ values were divid-
ed by the sum of all values to give the normalized IBAQ values. The 
average and range of the normalized IBAQ values for each protein are 
shown in Figure 2, B and C. To determine the proportion of the aver-
age normalized IBAQ values that arose at each time point of infection, 
the IBAQ values were adjusted in proportion to the normalized tan-
dem mass tag (TMT) values shown in Figure 2A.
Protein purification and labeling. Soluble UL141 and UL16 were 
produced in HFFF-hCARs transduced with RAd-sUL141 or RAd-
sUL16, respectively, over a 10-day period at a MOI of 40 PFU/cell. 
Supernatants were collected and purified using Strep-Tactin (IBA 
GmbH) or HisTrap HP Columns (GE Healthcare). Both proteins were 
subjected to buffer exchange in PBS and fluorescently labeled using 
the Alexa Fluor 647 Protein Labeling Kit (Thermo Fisher Scientific).
Ab isolation. PBMCs were isolated from a healthy HCMV-seropos-
itive donor, and IgG+ memory B cells were isolated using an IgG+ Mem-
ory B Cell Isolation Kit (Miltenyi Biotec). The enriched B cells were 
stained for 30 minutes at 4oC with 2 μg/mL Alexa Fluor 647–labeled 
protein (soluble UL141 or UL16) and flow sorted using a BD FACSAria 
III (BD Biosciences). Single cells were sorted into individual wells con-
taining Ms40L low feeder cells, 10% FCS, 5% human AB serum, IL-4 
(10 ng/mL), BAFF (10 ng/mL), IL-21 (10 ng/mL), and IL-2 (50 ng/
mL) in a final volume of 100 μL (all cytokines were from Peprotech). 
Cultures were supplemented with an additional 100 μL of the same 
medium 1 week later. Two weeks after coculturing, 50 μL supernatant 
from each of the single-cell colonies was screened by flow cytometry 
for binding to UL141 (RAd-UL141ΔER) and UL16 (RAd-UL16ΔER). 
RNA was extracted from the cells that were positive for binding using 
the RNEasy Plus Kit (QIAGEN). The Ab sequence was determined by 
nested reverse transcription PCR (RT-PCR) as described previously 
(88). Sequences were analyzed by the IgBLAST tool to identify the V 
were grown in Gibco Expi293 Expression Medium (Thermo Fisher Sci-
entific). Ms40L low cells were a gift from Garnett Kelsoe (Duke Uni-
versity, Durham, North Carolina, USA) and David Baltimore (Caltech, 
Pasadena, California, USA) (79, 80). They were kept in DMEM supple-
mented as above with the addition of 50 μM β-mercaptoethanol.
Viruses. All viruses were derived from a bacterial artificial chro-
mosome (BAC) containing the complete wild-type HCMV genome, 
with the exception of RL13 and UL128, since the absence of these 
genes enhances stability in fibroblasts (20, 81). Mutations were engi-
neered using either recombineering or en passant mutagenesis, as 
described previously (20, 82–85). The primer sequences are listed 
in Table 1. Viruses were generated by transfection of BACs (20) into 
HF-TERTs and titrated on HFFFs. All modifications were sequence 
verified prior to BAC transfection, and all viruses were sequenced 
at the whole-genome level following reconstitution to exclude the 
occurrence of second-site mutations (86).
RAds were generated as described previously (84). They were 
as follows: RAd-Ctrl (no exogenous protein-coding region); RAd-
UL141ΔER (expressing UL141 carrying a deletion of the cytoplasmic 
tail and an exogenous signal peptide containing an HA tag after the 
cleavage site); RAd-UL16ΔER (expressing UL16 carrying a deletion of 
the cytoplasmic tail and an exogenous signal peptide containing an HA 
tag after the cleavage site); RAd-sUL141 (expressing the UL141 extra-
cellular domain with a C-terminal Strep-tag); RAd-sUL16 (expressing 
the UL16 extracellular domain with a C-terminal 6xHis-tag); RAd-
UL141 (expressing the native form of UL141; ref. 67); and RAd-UL16 
(expressing the native form of UL16). RAds expressing other HCMV 
proteins have been described previously (84), and all contained a 
C-terminal V5 epitope tag. All RAds were propagated by transfection of 
the relevant plasmids into 293 TREX cells as described previously (84).
Proteomics. Data originally published by Weekes et al. (45) were 
reanalyzed to estimate the absolute abundance of each cell-surface 
viral protein. To be included in this analysis, proteins required quan-
titation, in both experiments PM1 and PM2, of 2 or more peptides in 
at least 1 of the 2 experiments. Overall, this included 27 of 29 of the 
viral proteins we originally measured. Experiment PM1 examined 
cells infected with strain Merlin in biological duplicates at 0 hours, 24 
hours, 48 hours, and 72 hours. Reanalysis was based on the mean val-
ues for each time point. Experiment PM2 examined cells infected with 
the same HCMV strain in single replicates at 0 hours, 6 hours, 12 hours, 
18 hours, 24 hours, 48 hours, 72 hours, and 96 hours. In reanalysis, the 
mean values for time point 0 were used, and infection with irradiated 
HCMV at 12 hours was excluded from analysis. In Figure 2A, for experi-
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Flow Cytometer (Thermo Fisher Scientific) and analyzed with Attune 
NxT software or FlowJo software, version 10 (Tree Star). All assays 
were repeated with samples from multiple donors. When used directly 
ex vivo, NK cells from different donors can vary significantly in the 
magnitude of their responses, thus, only experiments where results 
showed consistent patterns between donors are included. Donors 
included both HCMV-seropositive and -seronegative individuals.
Chromium release cytotoxicity assays. Assays were performed as 
previously described (91). In brief, targets were incubated with 150 
μCi sodium chromate (51Cr) for 1 hour, washed and allowed to leach 
for 1 hour, and then incubated with purified NK cells and Abs. After 
4 hours, supernatants were removed and mixed with scintillation 
fluid (Optiphase HiSafe 3, PerkinElmer), before reading the cpm in a 
MicroBeta 2 (PerkinElmer). Maximum lysis was generated using 2.5% 
Triton X-100. Specific lysis was calculated as follows: (sample cpm – 
spontaneous cpm)/(maximum cpm – spontaneous cpm).
Viral dissemination assays. Assays were performed as previously 
described (54). Briefly, SFs were infected at a MOI of 0.05 with a virus 
containing a P2A-mCherry cassette after UL36, and an EGFP tag directly 
fused to UL32. At 24 hpi, purified ex vivo (NK Isolation Kit, Miltenyi Bio-
tec) autologous NK cells were added at a range of E/T ratios, in the pres-
ence or absence of Abs. After 8–10 days, nonadherent cells were washed 
off and discarded, and adherent cells were trypsinized, fixed in 4% PFA 
and analyzed by flow cytometry for mCherry and/or EGFP expression. 
To determine levels of the NK-mediated control, the percentage of flu-
orescent cells in the presence of Ab and NK cells was normalized to the 
percentage of fluorescent cells in the presence of Ab alone.
Immunoblotting. HFFF-hCARs were transduced with RAd-UL141 
or RAd-UL16 (MOI = 5 PFU/cell) for 48 hours. Whole-cell lysates were 
collected and boiled in reducing-denaturing Nu-PAGE lysis buffer 
(Thermo Fisher Scientific), separated by electrophoresis in Criterion 
TGX Gels (Bio-Rad) and transferred onto nitrocellulose membranes 
(GE Life Sciences). Membranes were blocked in TBS-T buffer with 5% 
dried nonfat milk and stained with either anti-V5 (clone CV5-Pk1, Bio-
Rad) or anti-actin (A2066, MilliporeSigma) Abs. Proteins were visual-
ized with SuperSignal West Pico PLUS Chemiluminescent Substrate 
(Thermo Fisher Scientific) and imaged on a GBOX-Chemi-XX6 gel 
documentation system (Syngene) operating GeneSys software.
Study approval. Healthy adult donors provided written informed 
consent for the collection of venous blood samples and dermal fibro-
blasts according to the principles of the Declaration of Helsinki. Study 
approval was granted by the Cardiff University School of Medicine 
Research Ethics Committee (reference number 16/52).
Statistics. Statistical significance was determined using a 1- or 
2-way ANOVA as appropriate, with Sidak’s post tests. A P value of 0.05 
or less was considered significant.
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of total plasmid DNA) using polyethylenimine (PEI) diluted in ultra-
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with protein G agarose beads. The following day, the bead-superna-
tant reactions were transferred to room temperature for 2 hours and 
then centrifuged at 3000g for 10 minutes. The beads were transferred 
to a chromatography column, washed with 5 resin-bed volumes of 1 M 
NaCl, and eluted twice with 2.5 resin-bed volumes of PBS. Abs were 
eluted into Tris-HCl, pH 9.0, with 2.5 resin-bed volumes of glycine 
buffer, pH 2.8 (Pierce, Thermo Fisher Scientific), ensuring that the 
final pH was approximately 7.0. The Abs were subsequently subjected 
to buffer exchange against PBS.
CD107a Assays. Degranulation assays were based on the flow 
cytometric detection of CD107a (90). PBMCs were rested overnight 
in RPMI supplemented with 10% FCS, penicillin (100 U/mL), strep-
tomycin (100 μg/mL), and l-glutamine (2 mM) in the absence or 
presence of IFN-α (1000 U/mL). HF-TERTs (allogeneic) or SFs (autol-
ogous) were plated in DMEM without FCS and infected the following 
day with HCMV (MOI = 5 PFU/cell). The medium was replaced 24 
hpi with DMEM containing 10% FCS. Assays were performed 48 hpi 
unless stated otherwise. Targets were harvested using TrypLE Express 
(Gibco, Thermo Fisher Scientific), preincubated for 30 minutes with 
the relevant Ab preparations, and mixed with PBMCs at an E/T ratio 
of 10:1 in the presence of GolgiStop (0.7 μL/mL, eBioscience) and 
anti–CD107a–PerCP-Cy5.5 (clone H4A3, BioLegend). Assays were 
performed in triplicate in U-bottomed, 96-well plates at a final vol-
ume of 200 μL/well. Background activation was determined in wells 
containing effectors without targets. Cells were incubated for 5 hours, 
washed in cold PBS, and stained with LIVE/DEAD Fixable Aqua 
(Thermo Fisher Scientific), anti–CD3-BV711 (clone UCHT1, BioLeg-
end), anti–CD56-BV605 (clone 5.1H11, BioLegend), anti–CD57-APC 
(clone HNK-1, BioLegend), and anti–NKG2C-PE (clone 134591, R&D 
Systems). In some experiments, cells were also fixed and permea-
bilized using Cytofix/Cytoperm (BD Biosciences) and stained with 
anti–TNF-α–BV421 (clone MAb11, BioLegend) and anti–IFN-γ–PE–
Cy7 (clone B27, BioLegend). Data were acquired using an Attune NxT 
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